Perspective | Published:

Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants

Nature Medicine volume 22, pages 238249 (2016) | Download Citation

Subjects

Abstract

Depression is a common, devastating illness. Current pharmacotherapies help many patients, but high rates of a partial response or no response, and the delayed onset of the effects of antidepressant therapies, leave many patients inadequately treated. However, new insights into the neurobiology of stress and human mood disorders have shed light on mechanisms underlying the vulnerability of individuals to depression and have pointed to novel antidepressants. Environmental events and other risk factors contribute to depression through converging molecular and cellular mechanisms that disrupt neuronal function and morphology, resulting in dysfunction of the circuitry that is essential for mood regulation and cognitive function. Although current antidepressants, such as serotonin-reuptake inhibitors, produce subtle changes that take effect in weeks or months, it has recently been shown that treatment with new agents results in an improvement in mood ratings within hours of dosing patients who are resistant to typical antidepressants. Within a similar time scale, these new agents have also been shown to reverse the synaptic deficits caused by stress.

  • Subscribe to Nature Medicine for full access:

    $225

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382, 1575–1586 (2013).

  2. 2.

    et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). J. Am. Med. Assoc. 289, 3095–3105 (2003).

  3. 3.

    et al. STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163, 28–40 (2006).

  4. 4.

    , & Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry 72, 334–341 (2015).

  5. 5.

    et al. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr. Serv. 60, 1439–1445 (2009).

  6. 6.

    , , , & Neurobiology of resilience. Nat. Neurosci. 15, 1475–1484 (2012).

  7. 7.

    , , , & Posterior hippocampal volumes are associated with remission rates in patients with major depressive disorder. Biol. Psychiatry 64, 880–883 (2008).

  8. 8.

    & Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci. Biobehav. Rev. 33, 699–771 (2009).

  9. 9.

    et al. Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat. Med. 18, 1413–1417 (2012).

  10. 10.

    & Synaptic dysfunction in depression: potential therapeutic targets. Science 338, 68–72 (2012).

  11. 11.

    , , & Stress and anxiety: structural plasticity and epigenetic regulation as a consequence of stress. Neuropharmacology 62, 3–12 (2012).

  12. 12.

    & The aging cortical synapse: hallmarks and implications for cognitive decline. Nat. Rev. Neurosci. 13, 240–250 (2012).

  13. 13.

    & Experience-dependent structural synaptic plasticity in the mammalian brain. Nat. Rev. Neurosci. 10, 647–658 (2009).

  14. 14.

    & Synaptic AMPA receptor plasticity and behavior. Neuron 61, 340–350 (2009).

  15. 15.

    , & Dendritic spine formation and stabilization. Curr. Opin. Neurobiol. 19, 146–153 (2009).

  16. 16.

    , , & Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov. 7, 426–437 (2008).

  17. 17.

    , , & The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat. Rev. Neurosci. 13, 22–37 (2012).

  18. 18.

    , & Epigenetics of the depressed brain: role of histone acetylation and methylation. Neuropsychopharmacology 38, 124–137 (2013).

  19. 19.

    & Epigenetic alterations in depression and antidepressant treatment. Dialogues Clin. Neurosci. 16, 395–404 (2014).

  20. 20.

    et al. Epigenetic programming by maternal behavior. Nat. Neurosci. 7, 847–854 (2004).

  21. 21.

    & The molecular neurobiology of depression. Nature 455, 894–902 (2008).

  22. 22.

    , & The cellular neurobiology of depression. Nat. Med. 7, 541–547 (2001).

  23. 23.

    & Treatment of mood disorders. Nat. Neurosci. 5, 1068–1070 (2002).

  24. 24.

    & Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy. Proc. Natl. Acad. Sci. USA 105, 359–364 (2008).

  25. 25.

    & Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: involvement of glucocorticoid secretion and excitatory amino acid receptors. Neuroscience 69, 89–98 (1995).

  26. 26.

    , & Effect of acute stress on hippocampal glutamate levels and spectrin proteolysis in young and aged rats. J. Neurochem. 65, 268–274 (1995).

  27. 27.

    , , & Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17, 2921–2927 (1997).

  28. 28.

    , , , & Epigenetic mechanisms for the early environmental regulation of hippocampal glucocorticoid receptor gene expression in rodents and humans. Neuropsychopharmacology 38, 111–123 (2013).

  29. 29.

    et al. Genetic determinants of depression: recent findings and future directions. Harv. Rev. Psychiatry 23, 1–18 (2015).

  30. 30.

    et al. REDD1 is essential for stress-induced synaptic loss and depressive behavior. Nat. Med. 20, 531–535 (2014).

  31. 31.

    & Synaptic versus extrasynaptic NMDA receptor signaling: implications for neurodegenerative disorders. Nat. Rev. Neurosci. 11, 682–696 (2010).

  32. 32.

    et al. Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J. Biol. Psychiatry 11, 763–773 (2010).

  33. 33.

    & A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 59, 1116–1127 (2006).

  34. 34.

    Brain-derived neurotrophic factor: role in depression and suicide. Neuropsychiatr. Dis. Treat. 5, 433–449 (2009).

  35. 35.

    , , & The fibroblast growth factor system and mood disorders. Biol. Psychiatry 59, 1128–1135 (2006).

  36. 36.

    et al. Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation. J. Neurosci. 29, 8688–8697 (2009).

  37. 37.

    , & Hippocampal cell proliferation regulation by repeated stress and antidepressants. Neuroreport 17, 863–867 (2006).

  38. 38.

    et al. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol. Psychiatry 71, 996–1005 (2012).

  39. 39.

    et al. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology 38, 2268–2277 (2013).

  40. 40.

    et al. Effect of brain-derived neurotrophic factor haploinsufficiency on stress-induced remodeling of hippocampal neurons. Hippocampus 21, 253–264 (2011).

  41. 41.

    , , & Gender-specific impact of brain-derived neurotrophic factor signaling on stress-induced depression-like behavior. Biol. Psychiatry 66, 84–90 (2009).

  42. 42.

    , , , & A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol. Psychiatry 61, 661–670 (2007b).

  43. 43.

    et al. Interactions between BDNFVal66Met polymorphism and early-life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol. Psychiatry 14, 681–695 (2009).

  44. 44.

    et al. Brain-derived neurotrophic factor–5-HTTLPR gene interactions and environmental modifiers of depression in children. Biol. Psychiatry 59, 673–680 (2006).

  45. 45.

    et al. Interactions between life stressors and susceptibility genes (5-HTTLPR and BDNF) on depression in Korean elders. Biol. Psychiatry 62, 423–428 (2007).

  46. 46.

    & mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 33, 67–75 (2010).

  47. 47.

    , & BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol. Learn. Mem. 89, 312–323 (2008).

  48. 48.

    TrkB signaling pathways in LTP and learning. Nat. Rev. Neurosci. 10, 850–860 (2009).

  49. 49.

    & mTOR and the health benefits of exercise. Semin. Cell Dev. Biol. 36, 130–139 (2014).

  50. 50.

    , , & Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 33, 70–75 (2009).

  51. 51.

    et al. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 1774–1779 (2011).

  52. 52.

    et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959–964 (2010).

  53. 53.

    et al. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis and antidepressant behavioral responses. Biol. Psychiatry 74, 742–749 (2013).

  54. 54.

    et al. Reduced phosphorylation of the mTOR signaling pathway components in the amygdala of rats exposed to chronic stress. Prog. Neuropsychopharmacol. Biol. Psychiatry 40, 240–245 (2013).

  55. 55.

    et al. Glutamate N-methyl-d-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 69, 754–761 (2011).

  56. 56.

    , & Endocrine factors in the etiology of postpartum depression. Compr. Psychiatry 44, 234–246 (2003).

  57. 57.

    & Hormones, heart disease and health: individualized medicine versus throwing the baby out with the bathwater. Depress. Anxiety 28, E1–E15 (2011).

  58. 58.

    & Estrogenic mediation of serotonergic and neurotrophic systems: implications for female mood disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 54, 13–25 (2014).

  59. 59.

    et al. Estrogen receptor neurobiology and its potential for translation into broad-spectrum therapeutics for CNS disorders. Curr. Mol. Pharmacol. 2, 215–236 (2009).

  60. 60.

    et al. Transient cyclical methylation of promoter DNA. Nature 452, 112–115 (2008).

  61. 61.

    & Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression. Neuroscience 251, 33–50 (2013).

  62. 62.

    , , & Astrocyte-derived growth factors and estrogen neuroprotection: role of transforming growth factor–α in estrogen-induced upregulation of glutamate transporters in astrocytes. Mol. Cell. Endocrinol. 389, 58–64 (2014).

  63. 63.

    et al. 17β-estradiol increases astrocytic vascular endothelial growth factor (VEGF) in adult female rat hippocampus. Endocrinology 152, 1745–1751 (2011).

  64. 64.

    & Influence of estradiol, stress and 5-HT2A agonist treatment on brain-derived neurotrophic factor expression in female rats. Biol. Psychiatry 54, 59–69 (2003).

  65. 65.

    et al. 17β-estradiol replacement in young, adult and middle-aged female ovariectomized rats promotes improvement of spatial reference memory and an antidepressant effect, and alters monoamines and BDNF levels in memory- and depression-related brain areas. Behav. Brain Res. 227, 100–108 (2012).

  66. 66.

    & The influence of gonadal hormones on neuronal excitability, seizures and epilepsy in the female. Epilepsia 47, 1423–1440 (2006).

  67. 67.

    et al. Estrogen alters spine number and morphology in prefrontal cortex of aged female rhesus monkeys. J. Neurosci. 26, 2571–2578 (2006).

  68. 68.

    & Stress-induced dendritic remodeling in the medial prefrontal cortex: effects of circuit, hormones and rest. Brain Res. 1293, 108–113 (2009).

  69. 69.

    & Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat. J. Neurosci. 12, 2549–2554 (1992).

  70. 70.

    et al. Estradiol-induced object memory consolidation in middle-aged female mice requires dorsal hippocampal extracellular signal–regulated kinase and phosphatidylinositol 3-kinase activation. J. Neurosci. 30, 4390–4400 (2010).

  71. 71.

    & Intrahippocampal estradiol infusion enhances memory in ovariectomized rats. Neuroreport 8, 3009–3013 (1997).

  72. 72.

    et al. Estrogen protects against the detrimental effects of repeated stress on glutamatergic transmission and cognition. Mol. Psychiatry 19, 588–598 (2014).

  73. 73.

    , , , & BDNF variant BDNFVal66Met interacts with estrous cycle in the control of hippocampal function. Proc. Natl. Acad. Sci. USA 107, 4395–4400 (2010).

  74. 74.

    & Estrogen receptors: therapies targeted to receptor subtypes. Clin. Pharmacol. Ther. 89, 44–55 (2011).

  75. 75.

    et al. Uncovering the mechanisms of estrogen effects on hippocampal function. Front. Neuroendocrinol. 29, 219–237 (2008).

  76. 76.

    , , , & Estradiol-induced object recognition memory consolidation is dependent on activation of mTOR signaling in the dorsal hippocampus. Learn. Mem. 20, 147–155 (2013).

  77. 77.

    , , , & 17β-estradiol regulates histone alterations associated with memory consolidation and increases Bdnf promoter acetylation in middle-aged female mice. Learn. Mem. 21, 457–467 (2014).

  78. 78.

    , , & Diabetes and depression comorbidity and socio-economic status in low- and middle-income countries (LMICs): a mapping of the evidence. Global. Health 8, 39 (2012).

  79. 79.

    et al. Overweight, obesity and depression: a systematic review and meta-analysis of longitudinal studies. Arch. Gen. Psychiatry 67, 220–229 (2010).

  80. 80.

    , & Is there a 'metabolic-mood syndrome'? A review of the relationship between obesity and mood disorders. Neurosci. Biobehav. Rev. 52, 89–104 (2015).

  81. 81.

    et al. Depression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis. PLoS One 8, e57058 (2013).

  82. 82.

    et al. Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl. Psychiatry 2, e79 (2012).

  83. 83.

    , & Inflammation, obesity and metabolic syndrome in depression: analysis of the 2009–2010 National Health and Nutrition Examination Survey (NHANES). J. Clin. Psychiatry 75, e1428–e1432 (2014).

  84. 84.

    , & Obesity and C-reactive protein in various populations: a systematic review and meta-analysis. Obes. Rev. 14, 232–244 (2013).

  85. 85.

    The hypothalamic-pituitary-adrenal axis and sex hormones in chronic stress and obesity: pathophysiological and clinical aspects. Ann. NY Acad. Sci. 1264, 20–35 (2012).

  86. 86.

    , & The link between depression and diabetes: the search for shared mechanisms. Lancet Diabetes Endocrinol. 3, 461–471 (2015).

  87. 87.

    & The brain reward circuitry in mood disorders. Nat. Rev. Neurosci. 14, 609–625 (2013).

  88. 88.

    , & Reward, dopamine and the control of food intake: implications for obesity. Trends Cogn. Sci. 15, 37–46 (2011).

  89. 89.

    , , & Overlapping neuronal circuits in addiction and obesity: evidence of systems pathology. Phil. Trans. R. Soc. Lond. B 363, 3191–3200 (2008).

  90. 90.

    , & Metabolism, mood and cognition in aging: the importance of lifestyle and dietary intervention. Neurobiol. Aging 26 (suppl. 1), 1–5 (2005).

  91. 91.

    , , & Leptin: a potential novel antidepressant. Proc. Natl. Acad. Sci. USA 103, 1593–1598 (2006).

  92. 92.

    et al. The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress. Nat. Neurosci. 11, 752–753 (2008).

  93. 93.

    , , & Ghrelin's role in the hypothalamic-pituitary-adrenal axis stress response: implications for mood disorders. Biol. Psychiatry 78, 19–27 (2015).

  94. 94.

    , , , & Peptides from adipose tissue in mental disorders. World J. Psychiatry 4, 103–111 (2014).

  95. 95.

    , , , & Gut microbes and the brain: paradigm shift in neuroscience. J. Neurosci. 34, 15490–15496 (2014).

  96. 96.

    et al. Gut-microbiota-brain axis and its effect on neuropsychiatric disorders with suspected immune dysregulation. Clin. Ther. 37, 984–995 (2015).

  97. 97.

    & Psychobiotics and the gut-brain axis: in the pursuit of happiness. Neuropsychiatr. Dis. Treat. 11, 715–723 (2015).

  98. 98.

    & Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective-spectrum disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 730–743 (2011).

  99. 99.

    et al. Impaired mitochondrial function in psychiatric disorders. Nat. Rev. Neurosci. 13, 293–307 (2012).

  100. 100.

    et al. Glutamate metabolism in major depressive disorder. Am. J. Psychiatry 171, 1320–1327 (2014).

  101. 101.

    , , & Depression and type 2 diabetes: a causal association? Lancet Diabetes Endocrinol. 2, 236–245 (2014).

  102. 102.

    , , & Metabolic syndrome: definitions and controversies. BMC Med. 9, 48 (2011).

  103. 103.

    The metabolic syndrome: time to get off the merry-go-round? J. Intern. Med. 269, 127–136 (2011).

  104. 104.

    et al. High-fat diet produces brain insulin resistance, synaptodendritic abnormalities and altered behavior in mice. Neurobiol. Dis. 67, 79–87 (2014).

  105. 105.

    & Experimental diabetes in rats causes hippocampal dendritic and synaptic reorganization and increased glucocorticoid reactivity to stress. Proc. Natl. Acad. Sci. USA 97, 11056–11061 (2000).

  106. 106.

    et al. Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats. Hippocampus 18, 1085–1088 (2008).

  107. 107.

    et al. Brain-derived neurotrophic factor–mediated effects on mitochondrial respiratory coupling and neuroprotection share the same molecular signaling pathways. Eur. J. Neurosci. 35, 366–374 (2012).

  108. 108.

    & BDNF mediates adaptive brain and body responses to energetic challenges. Trends Endocrinol. Metab. 25, 89–98 (2014).

  109. 109.

    & Hypothalamic BDNF and obesity: found in translation. Nat. Med. 18, 496–497 (2012).

  110. 110.

    , , , & Selective deletion of Bdnf in the ventromedial and dorsomedial hypothalamus of adult mice results in hyperphagic behavior and obesity. J. Neurosci. 27, 14265–14274 (2007).

  111. 111.

    et al. Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc. Natl. Acad. Sci. USA 112, 3463–3468 (2015).

  112. 112.

    et al. Skeletal muscle PGC-1α1 modulates kynurenine metabolism and mediates resilience to stress-induced depression. Cell 159, 33–45 (2014).

  113. 113.

    , , & Bridging animal and human models of exercise-induced brain plasticity. Trends Cogn. Sci. 17, 525–544 (2013).

  114. 114.

    Inflammatory markers in depression. Curr. Opin. Psychiatry 22, 32–36 (2009).

  115. 115.

    , & The inflammasome: pathways linking psychological stress, depression and systemic illnesses. Brain Behav. Immun. 31, 105–114 (2013).

  116. 116.

    , & Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65, 732–741 (2009).

  117. 117.

    , & Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 27, 24–31 (2006).

  118. 118.

    et al. A meta-analysis of cytokines in major depression. Biol. Psychiatry 67, 446–457 (2010).

  119. 119.

    , & Associations of depression with C-reactive protein, IL-1 and IL-6: a meta-analysis. Psychosom. Med. 71, 171–186 (2009).

  120. 120.

    & Malaise, melancholia and madness: the evolutionary legacy of an inflammatory bias. Brain Behav. Immun. 31, 1–8 (2013).

  121. 121.

    et al. Psychological stress activates the inflammasome via release of ATP and stimulation of the P2X7 receptor. Biol. Psychiatry doi:10.1016/j.biopsych.2015.11.026 (8 December 2015).

  122. 122.

    Immune proteins in brain development and synaptic plasticity. Neuron 64, 93–109 (2009).

  123. 123.

    et al. A dual role for interleukin-1 in hippocampal-dependent memory processes. Psychoneuroendocrinology 32, 1106–1115 (2007).

  124. 124.

    , , & A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int. J. Neuropsychopharmacol. 12, 561–578 (2009).

  125. 125.

    & Evidence that increased hippocampal expression of the cytokine interleukin-1β is a common trigger for age- and stress-induced impairments in long-term potentiation. J. Neurosci. 18, 2974–2981 (1998).

  126. 126.

    & Synaptic scaling mediated by glial TNF-α. Nature 440, 1054–1059 (2006).

  127. 127.

    et al. Synaptic pruning by microglia is necessary for normal brain development. Science 333, 1456–1458 (2011).

  128. 128.

    et al. Microglia sculpt postnatal neural circuits in an activity- and complement-dependent manner. Neuron 74, 691–705 (2012).

  129. 129.

    , & The complement system: an unexpected role in synaptic pruning during development and disease. Annu. Rev. Neurosci. 35, 369–389 (2012).

  130. 130.

    et al. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 131, 391–404 (2007).

  131. 131.

    et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70, 31–41 (2013).

  132. 132.

    & Neuronal plasticity and antidepressant actions. Trends Neurosci. 36, 259–267 (2013).

  133. 133.

    & Linking molecules to mood: new insight into the biology of depression. Am. J. Psychiatry 167, 1305–1320 (2010).

  134. 134.

    & The current state of the neurogenic theory of depression and anxiety. Curr. Opin. Neurobiol. 30, 51–58 (2015).

  135. 135.

    Genetic variant BDNFVal66Met polymorphism alters anxiety-related behavior. Science 314, 140–143 (2006b).

  136. 136.

    & Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci. 35, 47–56 (2012).

  137. 137.

    et al. Variant brain-derived neurotrophic factor Val66Met polymorphism alters vulnerability to stress and response to antidepressants. J. Neurosci. 32, 4092–4101 (2012).

  138. 138.

    et al. SKF83959 produces antidepressant effects in a chronic social-defeat stress model of depression through the BDNF-TrkB pathway. Int. J. Neuropsychopharmacol. 18, pyu096 (2015).

  139. 139.

    et al. Hippocampal structural and functional changes associated with electroconvulsive therapy response. Transl. Psychiatry 4, e483 (2014).

  140. 140.

    et al. Electroconvulsive therapy–induced brain plasticity determines therapeutic outcome in mood disorders. Proc. Natl. Acad. Sci. USA 111, 1156–1161 (2014).

  141. 141.

    et al. BDNFVal66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity. Neuropsychopharmacology 37, 1297–1304 (2012).

  142. 142.

    et al. Fear erasure in mice requires synergy between antidepressant drugs and extinction training. Science 334, 1731–1734 (2011).

  143. 143.

    et al. The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science 320, 385–388 (2008).

  144. 144.

    et al. Chronic fluoxetine treatment induces structural plasticity and selective changes in glutamate receptor subunits in the rat cerebral cortex. Neuroscience 169, 98–108 (2010).

  145. 145.

    et al. Hippocampal neurogenesis induced by antidepressant drugs: an epiphenomenon in their mood-improving actions. Mol. Psychiatry 14, 739 (2009).

  146. 146.

    & Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: comparison of stressors. Neuroscience 69, 83–88 (1995a).

  147. 147.

    Is mood chemistry? Nat. Rev. Neurosci. 6, 241–246 (2005).

  148. 148.

    et al. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47, 351–354 (2000).

  149. 149.

    et al. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 67, 793–802 (2010).

  150. 150.

    et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856–864 (2006).

  151. 151.

    et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-d-aspartate antagonist in patients with treatment-resistant major depressive disorder. J. Clin. Psychiatry 71, 1605–1611 (2010).

  152. 152.

    , , & Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol. Psychiatry 66, 522–526 (2009).

  153. 153.

    & Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol. Psychiatry 67, 432–438 (2010).

  154. 154.

    , , , & The promise of ketamine for treatment-resistant depression: current evidence and future directions. Ann. NY Acad. Sci. 1345, 47–58 (2015).

  155. 155.

    & Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology 40, 1307 (2015).

  156. 156.

    et al. GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. eLife 3, e03581 (2014).

  157. 157.

    et al. (R,S)-ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase mammalian target of rapamycin function. Anesthesiology 121, 149–159 (2014).

  158. 158.

    et al. Ketamine-induced antidepressant effects are associated with AMPA receptor–mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. Eur. Psychiatry 29, 419–423 (2014).

  159. 159.

    , , , & Ketamine strengthens CRF-activated amygdala inputs to basal dendrites in mPFC layer V pyramidal cells in the prelimbic but not the infralimbic subregion, a key suppressor of stress responses. Neuropsychopharmacology 40, 2066–2075 (2015).

  160. 160.

    et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5-methylisoxazole-4–propionic acid receptors. Biol. Psychiatry 63, 349–352 (2008).

  161. 161.

    & NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci. 27, 11496–11500 (2007).

  162. 162.

    et al. Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Mol. Psychiatry 17, 664–665 (2012).

  163. 163.

    et al. Brain-derived neurotrophic factor induces mammalian target of rapamycin–dependent local activation of translation machinery and protein synthesis in neuronal dendrites. J. Neurosci. 24, 9760–9769 (2004).

  164. 164.

    et al. NMDA receptor blockade at rest triggers rapid behavioral antidepressant responses. Nature 475, 91–95 (2011).

  165. 165.

    et al. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol. Psychiatry 71, 996–1005 (2012).

  166. 166.

    et al. Sub-anesthetic ketamine modulates intrinsic BOLD connectivity within the hippocampal-prefrontal circuit in the rat. Neuropsychopharmacology 39, 895–906 (2014).

  167. 167.

    et al. Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder. Transl. Psychiatry 5, e509 (2015).

  168. 168.

    et al. A placebo-controlled trial of the NR2B subunit–specific NMDA antagonist CP-101,606 plus paroxetine for treatment-resistant depression (TRD). (115th Annual Meeting of the American Psychological Association) (American Psychological Association, Washington, D.C., 2007).

  169. 169.

    et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol. Psychiatry 19, 978–985 (2014).

  170. 170.

    & Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior. Curr. Drug Targets 8, 583–602 (2007).

  171. 171.

    , , & Mood disorders: regulation by metabotropic glutamate receptors. Biochem. Pharmacol. 75, 997–1006 (2008).

  172. 172.

    et al. A negative regulator of MAP kinase causes depressive behavior. Nat. Med. 16, 1328–1332 (2010).

  173. 173.

    et al. Rapid antidepressant actions of scopolamine: role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors. Neurobiol. Dis. 82, 254–261 (2015).

  174. 174.

    et al. M1 and M2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine. J. Pharmacol. Exp. Ther. 351, 448–456 (2014).

  175. 175.

    , , , & Lurasidone exerts antidepressant properties in the chronic mild-stress model through the regulation of synaptic and neuroplastic mechanisms in the rat prefrontal cortex. Int. J. Neuropsychopharmacol. 18, pyu061 (2015).

  176. 176.

    et al. Antidepressant-like effects of erythropoietin: a focus on behavioral and hippocampal processes. PLoS One 8, e72813 (2013).

  177. 177.

    , & Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats. Neuropharmacology 82, 59–68 (2014).

  178. 178.

    et al. Monoacylglycerol lipase inhibition blocks chronic stress-induced depressive-like behaviors via activation of mTOR signaling. Neuropsychopharmacology 39, 1763–1776 (2014).

  179. 179.

    , & Genetic epidemiology of major depression: review and meta-analysis. Am. J. Psychiatry 157, 1552–1562 (2000).

  180. 180.

    et al. Meta-analyses of genetic studies on major depressive disorder. Mol. Psychiatry 13, 772–785 (2008).

  181. 181.

    et al. Genetic studies of major depressive disorder: why are there no genome-wide association study findings and what can we do about it? Biol. Psychiatry 76, 510–512 (2014).

  182. 182.

    Network and Pathway Analysis Subgroup of Psychiatric Genomics Consortium. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat. Neurosci. 18, 199–209 (2015).

  183. 183.

    et al. Social supports and serotonin transporter gene moderate depression in maltreated children. Proc. Natl. Acad. Sci. USA 101, 17316–17321 (2004).

  184. 184.

    Epigenetic mechanisms of depression. JAMA Psychiatry 71, 454–456 (2014).

  185. 185.

    , , & Epigenetic mechanisms underlying learning and the inheritance of learned behaviors. Trends Neurosci. 38, 96–107 (2015).

  186. 186.

    Cross-species studies of orbitofrontal cortex and value-based decision-making. Nat. Neurosci. 15, 13–19 (2012).

  187. 187.

    & Sensory and premotor connections of the orbital and medial prefrontal cortex of macaque monkeys. J. Comp. Neurol. 363, 642–664 (1995).

  188. 188.

    , , & The orbital and medial prefrontal circuit through the primate basal ganglia. J. Neurosci. 15, 4851–4867 (1995).

  189. 189.

    , & Architectonic subdivision of the human orbital and medial prefrontal cortex. J. Comp. Neurol. 460, 425–449 (2003).

  190. 190.

    & Neurocircuitry of mood disorders. Neuropsychopharmacology 35, 192–216 (2010).

  191. 191.

    , & A neural model of voluntary and automatic emotion regulation: implications for understanding the pathophysiology and neurodevelopment of bipolar disorder. Mol. Psychiatry 13 829, 833–857 (2008).

  192. 192.

    Differential projections of the infralimbic and prelimbic cortex in the rat. Synapse 51, 32–58 (2004).

  193. 193.

    , & The infralimbic cortex bidirectionally modulates mesolimbic dopamine neuron activity via distinct neural pathways. J. Neurosci. 33, 16865–16873 (2013).

  194. 194.

    et al. Identifying predictors, moderators and mediators of antidepressant response in major depressive disorder: neuroimaging approaches. Am. J. Psychiatry 172, 124–138 (2015).

  195. 195.

    Depression, stress and anhedonia: toward a synthesis and integrated model. Annu. Rev. Clin. Psychol. 10, 393–423 (2014).

Download references

Acknowledgements

This work was supported by the US National Institute of Mental Health grants MH045481 (R.S.D.) and MH093897 (R.S.D.), the National Center for Advancing Translational Science grant 1UH2TR000960-01 (J.H.K.), the National Institute on Alcohol Abuse and Alcoholism grants P50AA12870 (J.H.K.) and M01RR00125 (J.H.K.), the Yale Center for Clinical Investigation grant UL1 RR024139 (J.H.K.), the state of Connecticut's Department of Mental Health and Addiction Services (DMHAS; to R.S.D., G.K.A., G.S. and J.H.K.), the Yale University School of Medicine (R.S.D. and J.H.K.), the Brain and Behavior Research Foundation (G.S.), the Pfeiffer Research Foundation (G.S. and J.H.K.) and the National Center for Posttraumatic Stress Disorder (R.S.D., G.S. and J.H.K.).

Author information

Affiliations

  1. Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.

    • Ronald S Duman
    • , George K Aghajanian
    • , Gerard Sanacora
    •  & John H Krystal
  2. Department of Neurobiology, Yale University School of Medicine, New Haven, Connecticut, USA.

    • Ronald S Duman
    • , George K Aghajanian
    • , Gerard Sanacora
    •  & John H Krystal

Authors

  1. Search for Ronald S Duman in:

  2. Search for George K Aghajanian in:

  3. Search for Gerard Sanacora in:

  4. Search for John H Krystal in:

Competing interests

R.S.D. has served as a consultant for Pfizer, Eli Lilly and Company, Johnson and Johnson, Bristol-Myers Squibb, Lundbeck, Forest Laboratories, Taisho Pharmaceuticals, Sunovion Pharmaceuticals and Naurex. R.S.D. has also received research support from Eli Lilly and Company, Forest Laboratories, Taisho Pharmaceuticals, Sunovion Pharmaceuticals and Naurex. G.K.A. has no competing financial interests. G.S. has served as a consultant for Allergan, Alkermes, AstraZeneca, Avanier Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, Hoffman La-Roche, Janssen, Merck and Company, Navigen, Naurex, Noven Pharmaceuticals, Servier Pharmaceuticals, Taisho Pharmaceuticals, Takeda, Teva and Vistagen Therapeutics. G.S. has also received additional research contracts from AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Johnson and Johnson, Hoffman La-Roche, Merck and Company, Naurex and Servier over the last 24 months. Free medication was provided to G.S. for an NIH-sponsored study by Sanofi-Aventis. J.H.K. serves as a consultant for Amgen, AstraZeneca, Biogen, Biomedisyn, Forum Pharmaceuticals, Janssen Research and Development, Otsuka America, Sage Therapeutics, Sunovion and Takeda Industries. J.H.K. is on the scientific advisory board of Lohocla Research, Luc Therapeutics and Pfizer Pharmaceuticals and receives research support from Lohocla Research, Luc Therapeutics and Pfizer Pharmaceuticals. G.S. and J.H.K. hold shares in BioHaven Pharmaceuticals Holding Company and are co-inventors on a US patent (#8,778,979) held by Yale University.

Corresponding author

Correspondence to Ronald S Duman.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nm.4050

Rights and permissions

To obtain permission to re-use content from this article visit RightsLink.